Surmodics Inc
NASDAQ:SRDX

Watchlist Manager
Surmodics Inc Logo
Surmodics Inc
NASDAQ:SRDX
Watchlist
Price: 39.33 USD 0.36% Market Closed
Market Cap: 561.1m USD
Have any thoughts about
Surmodics Inc?
Write Note

Surmodics Inc
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Surmodics Inc
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Surmodics Inc
NASDAQ:SRDX
Gross Profit
$93.1m
CAGR 3-Years
2%
CAGR 5-Years
1%
CAGR 10-Years
7%
Becton Dickinson and Co
NYSE:BDX
Gross Profit
$9.2B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
8%
Boston Scientific Corp
NYSE:BSX
Gross Profit
$11B
CAGR 3-Years
13%
CAGR 5-Years
8%
CAGR 10-Years
8%
Stryker Corp
NYSE:SYK
Gross Profit
$14B
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
8%
Abbott Laboratories
NYSE:ABT
Gross Profit
$23B
CAGR 3-Years
-2%
CAGR 5-Years
5%
CAGR 10-Years
8%
Intuitive Surgical Inc
NASDAQ:ISRG
Gross Profit
$5.3B
CAGR 3-Years
12%
CAGR 5-Years
12%
CAGR 10-Years
14%
No Stocks Found

Surmodics Inc
Glance View

Market Cap
561.1m USD
Industry
Health Care

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. The company is headquartered in Eden Prairie, Minnesota and currently employs 389 full-time employees. The firm operates through two segments: Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices, as well as drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that includes coronary, peripheral, neurovascular and structural heart, among others. The IVD segment designs, develops and manufactures component products and technologies for diagnostic immunoassay, as well as molecular tests and biomedical research applications, with products that include protein stabilization reagents, substrates, surface coatings and antigens.

SRDX Intrinsic Value
15.29 USD
Overvaluation 61%
Intrinsic Value
Price

See Also

What is Surmodics Inc's Gross Profit?
Gross Profit
93.1m USD

Based on the financial report for Sep 30, 2024, Surmodics Inc's Gross Profit amounts to 93.1m USD.

What is Surmodics Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
7%

Over the last year, the Gross Profit growth was -14%. The average annual Gross Profit growth rates for Surmodics Inc have been 2% over the past three years , 1% over the past five years , and 7% over the past ten years .

Back to Top